Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units

Blood

Volumn 90, Issue 7, 1997, Pages 2529-2534

  Molldrem, Jeffrey J ^a,b   Clave, Emmanuel ^a   Jiang, Yin Zheng ^a   Mavroudis, Dimitrios ^a   Raptis, Anastasios ^a   Hensel, Nancy ^a   Agarwala, Vaishali ^a   Barrett, A John ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL SPECIFICITY; CHRONIC MYELOID LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; HLA SYSTEM; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0030841573     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.7.2529     Document Type: Article

References (17)

1. Drobyski WR, Ash RC, Casper JT, McAuliffe T, Horowitz MM, Lawton C, Keever C, Baxter-Lowe LA, Camitta B, Garbrecht F, Pietryga D, Hansen R, Chitambar CR, Anderson T, Flomenberg N: Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood 83:1980, 1994
2. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, et al: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86:2041, 1995
3. Giralt SA, Kolb HJ: Donor lymphocyte infusions. Curr Opin Oncol 8:96, 1996
4. Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis D, Hensel N, Fukushima P, Barrett AJ: Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 88:2450, 1996
5. Rammensee HG, Friede T, Stevanoviic S: MHC ligands and peptide motifs: first listing. Immunogenetics 41:178, 1995
6. Zweerink HJ, Gammon MC, Utz U, Sauma SY, Harrer T, Hawkins JC, Johnson RP, Sirotina A, Hermes JD, Walker BD, Biddison WE: Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells. J Immunol 150:1763, 1993
7. Zarour H, De Smet C, Lehmann F, Marchand M, Lethe B, Romero P, Boon T, Renauld JC: The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pme117/gp100. J Invest Dermatol 107:63, 1996
8. Sturrock AB, Franklin KF, Rao G, Marshall BC, Rebentisch MB, Lemons RS, Hoidal JR: Structure, chromosomal assignment, and expression of the gene for proteinase 3. J Biol Chem 267:21193, 1992
9. Dengler R, Munstermann U, al-Batran S, Hausner I, Faderl S, Nerl C, Emmerich B: Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. Br J Haematol 89:250, 1995
10. Brouwer E, Stegeman CA, Huitema MG, Limburg PC, Kallenberg CG: T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis (WG). Clin Exp Immunol 98:448, 1994
11. Boon T, Coulie P, Marchand M, Weynants P, Wolfel T, Brichard V: Genes coding for tumor rejection antigens: Perspectives for specific immunotherapy. Important Adv Oncol 10:53, 1994
12. Hooijberg E, Visseren MJ, van den Berk PC, Jellema AP, Romeijn P, Sein JJ, van der Voort EI, Hekman A, Ossendorp F, Melief CJ: Lysis of syngeneic tumor B cells by autoreactive cytotoxic T lymphocytes specific for a CD19 antigen-derived synthetic peptide. J Immunother Emphasis Tumor Immunol 19:346, 1996
13. Kawakami Y, Rosenberg SA: T-cell recognition of self peptides as tumor rejection antigens. Immunol Res 15:179, 1996
14. Marincola FM, Rivoltini L, Salgaller ML, Player M, Rosenberg SA: Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. J Immunother Emphasis Tumor Immunol 19:266, 1996
15. Schoenberger SP, Sercarz EE: Harnessing self-reactivity in cancer immunotherapy. Semin Immunol 8:303, 1996
16. Boussiotis VA, Freeman GJ, Gribben JG, Nadler LM: The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response. Immunol Rev 153:5, 1996
17. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, Castro-Malaspina H, Childs BH, Gillio AP, Kernan NA, et al: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261, 1995